Drug Profile
V 710
Alternative Names: 0657nI Staphylococcus aureus vaccine - Merck; S.aureus vaccine - Merck; Staphylococcus aureus vaccine - Merck; V-710Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Intercell
- Developer Merck & Co
- Class Bacterial vaccines; Surface antigens
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 28 May 2013 Intercell has merged with Vivalis to form Valneva
- 09 Jun 2011 Merck and Intercell terminate their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America due to efficacy concerns (NCT00518687)
- 18 Apr 2011 Merck and Intercell suspend their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America (NCT00518687)